SPY337.92+0.48 0.14%
DIA279.63-0.41 -0.15%
IXIC11,111.89+99.65 0.90%

Ocugen shares are trading higher after the company announced that it was granted FDA Orphan drug designation for its OCU400 gene therapy for the treatment of RHO Mutation associated with retinal degenerative disease.

Benzinga · -